Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, People's Republic of China.
Clin Interv Aging. 2020 Mar 20;15:431-439. doi: 10.2147/CIA.S243902. eCollection 2020.
To explore the survival value of cytoreductive partial nephrectomy (cPN) in elderly with metastatic renal cell carcinoma (EmRCC) and evaluate the characteristics of patients who benefit from cPN.
This was a study including 6105 patients aged ≥65 years with metastatic renal cell carcinoma (RCC) queried from Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2015, among which 1264 patients underwent cytoreductive nephrectomy (CN), 78 patients underwent cPN and 1186 patients underwent cytoreductive radical nephrectomy (cRN). Kaplan-Meier (K-M) method and Cox proportional-hazards model (COX) were used to evaluate the survival prognosis. Overall survival (OS) was compared between groups using propensity score matching (PSM) to balance the effects of confounding factors such as general features and pathological features. At last, we constructed a nomogram visualization modelled by R language to predict survival.
For patients with EmRCC, especially for male patients with tumors size ≤7 cm, N0 stage, or isolated metastases, cPN brought a better survival than cRN. Tumor size and N stage were independent risk factors affecting the survival of cPN patients. cPN for patients with tumor size >7 cm or N1 stage may present a higher risk of death.
The implementation of cPN for patients with EmRCC who meet specific clinical characteristics such as tumors size ≤7 cm, N0 stage, or isolated metastases seems to help improve the survival prognosis.
探讨细胞减灭性部分肾切除术(cPN)在老年转移性肾细胞癌(EmRCC)患者中的生存价值,并评估从 cPN 中获益的患者特征。
本研究纳入了 2010 年至 2015 年期间从监测、流行病学和最终结果(SEER)数据库中查询的 6105 例年龄≥65 岁的转移性肾细胞癌(RCC)患者,其中 1264 例行细胞减灭性肾切除术(CN),78 例行 cPN,1186 例行细胞减灭性根治性肾切除术(cRN)。采用 Kaplan-Meier(K-M)法和 Cox 比例风险模型(COX)评估生存预后。采用倾向评分匹配(PSM)来平衡一般特征和病理特征等混杂因素的影响,比较各组之间的总生存(OS)。最后,我们使用 R 语言构建了一个列线图可视化模型来预测生存。
对于 EmRCC 患者,尤其是肿瘤大小≤7cm、N0 期或孤立转移的男性患者,cPN 比 cRN 带来更好的生存。肿瘤大小和 N 分期是影响 cPN 患者生存的独立危险因素。对于肿瘤大小>7cm 或 N1 期的患者,cPN 可能会增加死亡风险。
对于符合特定临床特征(如肿瘤大小≤7cm、N0 期或孤立转移)的 EmRCC 患者实施 cPN,似乎有助于改善生存预后。